CL2010001445A1 - Polipetidos mediadores de la salida de colesterol; peptidomimeticos; composicion y kit que lo comprende y su uso para tratar aterosclerosis. - Google Patents

Polipetidos mediadores de la salida de colesterol; peptidomimeticos; composicion y kit que lo comprende y su uso para tratar aterosclerosis.

Info

Publication number
CL2010001445A1
CL2010001445A1 CL2010001445A CL2010001445A CL2010001445A1 CL 2010001445 A1 CL2010001445 A1 CL 2010001445A1 CL 2010001445 A CL2010001445 A CL 2010001445A CL 2010001445 A CL2010001445 A CL 2010001445A CL 2010001445 A1 CL2010001445 A1 CL 2010001445A1
Authority
CL
Chile
Prior art keywords
peptidomimetics
cholesterol
kit
composition
treat atherosclerosis
Prior art date
Application number
CL2010001445A
Other languages
English (en)
Spanish (es)
Inventor
John K Johansson Jan Bielicki
Original Assignee
The Regents Of The Univresity Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The Univresity Of California filed Critical The Regents Of The Univresity Of California
Publication of CL2010001445A1 publication Critical patent/CL2010001445A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2010001445A 2008-06-18 2010-12-16 Polipetidos mediadores de la salida de colesterol; peptidomimeticos; composicion y kit que lo comprende y su uso para tratar aterosclerosis. CL2010001445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7370808P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
CL2010001445A1 true CL2010001445A1 (es) 2012-03-16

Family

ID=41434685

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001445A CL2010001445A1 (es) 2008-06-18 2010-12-16 Polipetidos mediadores de la salida de colesterol; peptidomimeticos; composicion y kit que lo comprende y su uso para tratar aterosclerosis.

Country Status (14)

Country Link
US (1) US8415293B2 (enExample)
EP (1) EP2300038A4 (enExample)
JP (1) JP2011525181A (enExample)
KR (1) KR20110043597A (enExample)
CN (1) CN102123722A (enExample)
AU (1) AU2009260024A1 (enExample)
BR (1) BRPI0915422A2 (enExample)
CA (1) CA2727465A1 (enExample)
CL (1) CL2010001445A1 (enExample)
IL (1) IL209868A0 (enExample)
MX (1) MX2010014003A (enExample)
PE (1) PE20110106A1 (enExample)
RU (1) RU2011101536A (enExample)
WO (1) WO2009155366A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139819A2 (en) * 2010-04-28 2011-11-10 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
CN105050614B (zh) * 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
US11091529B2 (en) 2014-09-17 2021-08-17 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
DK3319980T3 (da) * 2015-07-10 2021-11-22 Peptinovo Biopharma Inc Formuleringer til forbedring af virkningen af hydrofobe lægemidler
EP3464613A4 (en) 2016-05-31 2020-01-08 Institut de Cardiologie de Montréal CO-CULTURE SYSTEM AND METHOD FOR IN-VITRO EVALUATION OF CHOLESTERIN RETURN
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN111848742B (zh) * 2020-07-23 2021-03-23 南京医科大学 一种多肽及其制药用途
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CA2672131C (en) 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux

Also Published As

Publication number Publication date
CA2727465A1 (en) 2009-12-23
AU2009260024A1 (en) 2009-12-23
WO2009155366A3 (en) 2010-04-22
CN102123722A (zh) 2011-07-13
BRPI0915422A2 (pt) 2017-06-27
JP2011525181A (ja) 2011-09-15
US8415293B2 (en) 2013-04-09
RU2011101536A (ru) 2012-07-27
PE20110106A1 (es) 2011-03-02
IL209868A0 (en) 2011-02-28
KR20110043597A (ko) 2011-04-27
MX2010014003A (es) 2011-02-15
EP2300038A2 (en) 2011-03-30
EP2300038A4 (en) 2013-09-04
US20110190196A1 (en) 2011-08-04
WO2009155366A2 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
CL2010001445A1 (es) Polipetidos mediadores de la salida de colesterol; peptidomimeticos; composicion y kit que lo comprende y su uso para tratar aterosclerosis.
CL2012003516A1 (es) Compuesto derivado de 5-fenil-5-trifluorometil-4,5-dihidroisoxazol; composicion que lo comprende; y su uso para controlar piojos de mar en peces.
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
CL2010001530A1 (es) Compuestos derivados de tiadiazoliloxifenilamidinas; su procedimiento de preparacion; agentes para combatir microorganismos indeseados que comprende a dichos compuestos; uso; procedimiento para combatir microorganismos indeseados; y compuestos intermediarios.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
ECSP11011417A (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
ECSP12012307A (es) Proteínas de unión a il-1
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
SV2011003834A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0919193A2 (pt) Uso de lipídeo, e, composição nutricional
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
UY33124A (es) Agentes y epítopos enlazados a wise
ECSP11011297A (es) Proteinas ligadoras il-17
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
BRPI0913739A2 (pt) Composição líquida, método, e, uso de composição
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
BRPI0907365A2 (pt) Composição antimicrobiana e uso
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
BRPI0814420A2 (pt) composição, e, uso de álcool alcoxilado.
CL2008003712A1 (es) Compuestos derivados de tiadiazololoxifenilamidina o tiazoliloxifenilamidina; su procedimiento de preparacion; uso y procedimiento para combatir microorganismos no deseados; agente que comprende a dichos compuestos; compuestos intermediarios; y su procedimiento de preparacion.